| pubmed-article:8422470 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8422470 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8422470 | lifeskim:mentions | umls-concept:C0003241 | lld:lifeskim |
| pubmed-article:8422470 | lifeskim:mentions | umls-concept:C0013081 | lld:lifeskim |
| pubmed-article:8422470 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:8422470 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:8422470 | lifeskim:mentions | umls-concept:C2362067 | lld:lifeskim |
| pubmed-article:8422470 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:8422470 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:8422470 | lifeskim:mentions | umls-concept:C0439828 | lld:lifeskim |
| pubmed-article:8422470 | lifeskim:mentions | umls-concept:C1549003 | lld:lifeskim |
| pubmed-article:8422470 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:8422470 | pubmed:dateCreated | 1993-2-23 | lld:pubmed |
| pubmed-article:8422470 | pubmed:abstractText | Approximately 30% to 40% of patients with acute leukemia receiving repeated pooled random-donor platelet transfusions develop anti-HLA alloantibodies. Over time, however, serum anti-HLA concentrations decrease in approximately 50% of these patients, despite continued exposure to platelet and/or red blood cell transfusions. Using an enzyme-linked immunosorbent assay to measure serum Igs, the present study demonstrates that the sera of 67% of 82 transfused patients exhibiting a decrease in anti-HLA contain antibodies (anti-idiotypes) that react with the variable (V) region of anti-HLA antibodies. Anti-HLA binding to platelet membranes could be inhibited by these serum antibodies in 36% of the patients, indicating they had paratope-related reactivity. Protein G sepharose absorption showed that the anti-HLA V region-reactive antibodies were IgG. Of the 43 patients who had a decrease in anti-HLA levels, that were 16 whose anti-HLA decreased to undetectable levels; 7 (44%) developed anti-idiotypic antibodies that could specifically inhibit their own previously anti-HLA-positive serum. In contrast, antibodies with reactivity to the V region of anti-HLA antibodies (anti-idiotypes) were not demonstrable in patients who developed anti-HLA that did not decrease or disappear. The findings suggest that the development of anti-HLA V region-reactive antibodies (anti-idiotypic antibodies) correlates with a decrease in anti-HLA antibody formation in patients multiply transfused with platelet concentrates. The observations indicate that anti-idiotypic antibodies may downregulate alloimmune responses in patients undergoing repeated allostimulation during platelet transfusion therapy. | lld:pubmed |
| pubmed-article:8422470 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8422470 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8422470 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8422470 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8422470 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8422470 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8422470 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8422470 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8422470 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8422470 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:8422470 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:8422470 | pubmed:author | pubmed-author:FreedmanJJ | lld:pubmed |
| pubmed-article:8422470 | pubmed:author | pubmed-author:AtlanHH | lld:pubmed |
| pubmed-article:8422470 | pubmed:author | pubmed-author:KazatchkineM... | lld:pubmed |
| pubmed-article:8422470 | pubmed:author | pubmed-author:BlanchetteVV | lld:pubmed |
| pubmed-article:8422470 | pubmed:author | pubmed-author:SempleJ WJW | lld:pubmed |
| pubmed-article:8422470 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8422470 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:8422470 | pubmed:volume | 81 | lld:pubmed |
| pubmed-article:8422470 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8422470 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8422470 | pubmed:pagination | 538-42 | lld:pubmed |
| pubmed-article:8422470 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8422470 | pubmed:meshHeading | pubmed-meshheading:8422470-... | lld:pubmed |
| pubmed-article:8422470 | pubmed:meshHeading | pubmed-meshheading:8422470-... | lld:pubmed |
| pubmed-article:8422470 | pubmed:meshHeading | pubmed-meshheading:8422470-... | lld:pubmed |
| pubmed-article:8422470 | pubmed:meshHeading | pubmed-meshheading:8422470-... | lld:pubmed |
| pubmed-article:8422470 | pubmed:meshHeading | pubmed-meshheading:8422470-... | lld:pubmed |
| pubmed-article:8422470 | pubmed:meshHeading | pubmed-meshheading:8422470-... | lld:pubmed |
| pubmed-article:8422470 | pubmed:meshHeading | pubmed-meshheading:8422470-... | lld:pubmed |
| pubmed-article:8422470 | pubmed:meshHeading | pubmed-meshheading:8422470-... | lld:pubmed |
| pubmed-article:8422470 | pubmed:meshHeading | pubmed-meshheading:8422470-... | lld:pubmed |
| pubmed-article:8422470 | pubmed:meshHeading | pubmed-meshheading:8422470-... | lld:pubmed |
| pubmed-article:8422470 | pubmed:meshHeading | pubmed-meshheading:8422470-... | lld:pubmed |
| pubmed-article:8422470 | pubmed:meshHeading | pubmed-meshheading:8422470-... | lld:pubmed |
| pubmed-article:8422470 | pubmed:meshHeading | pubmed-meshheading:8422470-... | lld:pubmed |
| pubmed-article:8422470 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8422470 | pubmed:articleTitle | Downregulation of the anti-HLA alloimmune response by variable region-reactive (anti-idiotypic) antibodies in leukemic patients transfused with platelet concentrates. | lld:pubmed |
| pubmed-article:8422470 | pubmed:affiliation | Division of Hematology, St. Michael's Hospital, Toronto, Ontario, Canada. | lld:pubmed |
| pubmed-article:8422470 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8422470 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8422470 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8422470 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8422470 | lld:pubmed |
